Construction of Epitope-Based Peptide Vaccine Against SARS-CoV-2: Immunoinformatics Study

Construction of Epitope-Based Peptide Vaccine Against SARS-CoV-2: Immunoinformatics Study

Arif Nur Muhammad Ansori, Viol Dhea Kharisma

Recently, a novel coronavirus (SARS-CoV-2) appeared which is conscientious for the current outbreakin China and rapidly spread worldwide. Unluckily, there is no approved vaccine found against SARSCoV-2. Therefore, there is an urgent need for designing a suitable peptide vaccine constituent againstthe SARS-CoV-2. In this study, we characterized the spike glycoprotein of SARS-CoV-2 to obtainimmunogenic epitopes. In addition, we used 58 SARS-CoV-2 isolates were retrieved from the GlobalInitiative on Sharing All Influenza Data (GISAID) and National Center for Biotechnology Information(NCBI), then aligned to obtain the conserved region of SARS-CoV-2 spike glycoprotein. The interactionbetween the conserved region with ACE2 receptor, a SARS-CoV-2 receptor on the host cell, has beenevaluated through molecular docking approach. The B-cell epitope was identified using the immuneepitope database (IEDB) web server. Interestingly, we recommend Pep_4 ADHQPQTFVNTELH as aepitope-based peptide vaccine candidate to deal with the SARS-CoV-2 outbreak. Pep_4 has a high levelof immunogenicity and does not trigger autoimmune mechanisms. Pep_4 is capable of forming BCR/Fab molecular complexes with the lowest binding energy for activation of transduction signal the directB-cell immune response. However, further study is suggested for confirmation (in vitro and in vivo).

2020

coronavirus, immunoinformatics, SARS-CoV-2, epitope-based peptide vaccine

DOI: 10.22207/JPAM.14.SPL1.38

Journal of Pure and Applied Microbiology

Journal of Pure and Applied Microbiology

Microbiology